Download PDF
Diabetes aktuell 2009; 7(5): 238-245
DOI: 10.1055/s-0029-1239999
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Klinischer Nutzen der inkretinbasierten Therapien – Verbesserte Behandlung bei Typ–2–Diabetes

Beneficial Effects of Inkretin–based Therapy – Improved Therapy of Type–2–DiabetesMartin Schönauer1 , Claudia Walther2
  • 1Diabetes–Schwerpunktpraxis Leipzig
  • 2Herzzentrum Leipzig
Further Information

Publication History

Publication Date:
26 August 2009 (online)

Also available at
    Permissions and Reprints

Die Therapie des Typ–2–Diabetes ist nach wie vor schwierig. Therapeutische Ziele werden häufig nicht erreicht, und die Erkrankung einschließlich der mikro– und makrovaskulären Folgeerscheinungen schreitet fort. Inkretinbasierte Therapien haben neben der Wirkung auf die Glukosehomöostase und Besserung der Funktion der pankreatischen Betazellen weitere Effekte wie Senkung von Körpergewicht und Blutdruck, die die Situation und Lebensqualität des Patienten mit Typ–2–Diabetes langfristig möglicherweise günstig beeinflussen können.

Therapy of diabetes mellitus type 2 is still difficult. The therapeutic goals are often not reached, the disease with micro– and macrovascular sequelaes is progressing. Inkretin–based therapies have besides the effects on glucose homeostasis further and amelioration of the pancreatic beta cell function further beneficial effects on body weight and blood pressure. These effects can possibly improve the situation and quality of life of a patient with type 2 diabetes.

Key words

Diabetes mellitus type 2 - cardiovascular risk - Inkretinmimetics - DPP–4–inhibitors - Exenatide - Liraglutide - Sitagliptin - Vildagliptin

Literatur

  • 1 Scherbaum W, Haak T.. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenz–basierten Leitlinie der Deutschen Diabetes–Gesellschaft; 2008. Oktober 2008.  www.deutsche-diabetes-gesellschaft.de
    Google Scholar
  • 2 Pitocco D, Valle D, Rossi A, Gentilella R.. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti–diabetic agents.  J Endocrinol Invest. 2008;  31 371-379
    Google Scholar
  • 3 Nauck M, Stöckmann F. et al. . Reduced incretin eff ect in type 2 (non–insulin–dependent) diabetes.  Diabetologia. 1986;  29 46-52
    CrossrefPubMedGoogle Scholar
  • 4 Chia CW, Egan JM.. Incretin–based therapies in type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2008;  93 3703-3716
    CrossrefGoogle Scholar
  • 5 Meier JJ, Schmidt WE, Klein HH.. New concepts in the treatment of type 2 diabetes.  Internist. 2007;  48 700-707
    Google Scholar
  • 6 Madsbad S.. Liraglutide eff ect and action in diabetes (LEAD) trial.  Expert Rev Endocrinol Metab. 2009;  4 119-129
    CrossrefGoogle Scholar
  • 7 Marre M, Shaw J. et al. .Liraglutide, a once–dailyhuman GLP–1 analog, added to a sulfonylurea off ers signifi – cantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. ADA, 68th Scientifi c Sessions:13–0R
    Google Scholar
  • 8 Nauck M, Frid A. et al. . Effi cacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide eff ect and action in diabetes)–2 study.  Diabetes Care. 2009;  32 84-90
    CrossrefGoogle Scholar
  • 9 Garber A, Henry R. et al. . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD–3 Mono): a randomised, 52–week, phase III, doubleblind, parallel–treatment trial.  Lancet. 2009;  373 473-481
    CrossrefPubMedGoogle Scholar
  • 10 Zinman B, Gerich J, Buse JB. et al. .Effi cacy and safety of the human GLP–1–analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD–4 Met+TZD). Diabetes Care 2009: 08-2124
    Google Scholar
  • 11 Russell–Jones D, Vaag A. et al. . Signifi cantly better glycemic control and weight reduction with liraglutide, a once–daily human GLP–1 analog, compared with insulin glargine: all as add–on to metformin and a sulfonylurea in type–2 diabetes.  Diabetes. 2008;  57
    Google Scholar
  • 12 Blonde L, Rosenstock J. et al. .Liraglutide: superior glycemic control vs exenatide when added to metformin and/ode SU in type 2 diabetes. Canadian Diabetes Association Annual General Meeting, Montreal, 16. Oktober 2008
    Google Scholar
  • 13 Jendle J, Emamaullee JA.. Liraglutide, a once–daily human GLP–1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes. ADA, 68th Scientifi c Sessions 2008
    Google Scholar
  • 14 Colagiuri S, Frid A. et al. .The once–daily human GLP–1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. ADA, 68th Scientifi c Sessions
    Google Scholar
  • 15 UK Prospective Diabetes Study (UKPDS) Group. . U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.  Diabetes. 1995;  44 1249-1258
    CrossrefGoogle Scholar
  • 16 Amori RE, Lau J. et al. . Effi cacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta–analysis.  JAMA. 2007;  298 194-206
    CrossrefPubMedGoogle Scholar
  • 17 Fischer S, Bornstein SR.. Neue orale Antidiabetika. Klinische Perspektiven.  Internist. 2008;  49 495-501
    CrossrefGoogle Scholar
  • 18 Nauck MA.  Inkretinmimetika und Inkretinverstärker. Neue Diabetesmedikamente auf der Basis physiologischer insulinsekretionssteigernder Darmhormone.  Diabetologe. 2007;  3 387-398
    CrossrefGoogle Scholar
  • 19 Mistry GC, Maes AL, Lasseter KC. et al. . Eff ect of sita glitpin, a dipeptidyl–peptidase–4 inhibitor, on blood pressure in nondiabetic patients mit mild to moderate hypertension.  J Clin Pharmacol. 2008;  48 592-598
    Google Scholar
  • 20 Raz I, Hanefeld M, Xu L. et al. . Effi cacy and safety of the dipeptidyl peptidase IV inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.  Dia betologia. 2006;  49 2564-2571
    CrossrefPubMedGoogle Scholar
  • 21 Skyler JS, Bergenstal R. et al. . Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientifi c statement of the American College of Cardiology Foundation and the American Heart Association.  Diabetes Care. 2009;  32 187-192
    CrossrefGoogle Scholar
  • 22 UK Prospective Diabetes Study (UKPDS) Group. . Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33).  Lancet. 1998;  352 837-853
    CrossrefGoogle Scholar
  • 23 Holman RR, Paul SK. et al. . 10–year follow–up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
    CrossrefPubMedGoogle Scholar
  • 24 Drucker DJ, Nauck MA.. The incretin system: glucagon–like peptide–1 receptor agonists and dipeptidyl peptidase–4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
    CrossrefPubMedGoogle Scholar
  • 25 Fachinformation. Byetta. Fachinformation 2009; (März 2009). 
    Google Scholar
  • 26 Gallwitz B.. Liraglutide.  Drugs of the Future. 2008;  33 13-20
    CrossrefGoogle Scholar
  • 27 Klonoff DC, Buse JB, Nielsen LL. et al. . Exenatide eff ects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.  Curr Med Res Opin. 2008;  24 275-286
    CrossrefGoogle Scholar

Korrespondenz

Dr. Martin Schönauer

Facharzt für Innere und Allgemeinmedizin, Diabetologie Gemeinschaftspraxis Dr. Schönauer Akademische Lehrpraxis der Universität Leipzig

August–Bebel–Straße 71

04275 Leipzig

Email: praxis@schoenauer-leipzig.de

      >